Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2020-06-17 Board/Management Inform…
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
8-K RE TURKEL COHEN DEPARTURES
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes announcements of a reduction in force, termination of the President, and resignation of a board member. These are changes in the company's board of directors and senior management. There are no financial statements or detailed financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a proxy statement or voting results announcement. The primary focus is on management and board changes, which fits the Board/Management Information category (MANG). The document length is 5893 characters, sufficient to contain substantive information rather than a brief announcement. Therefore, the correct classification is MANG with high confidence.
2020-06-17 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 15, 2020, reporting the company's financial results for the period ended March 31, 2020. It specifically states that the full text of the press release announcing these results is furnished as an exhibit and incorporated by reference. The document is relatively short (4081 characters) and primarily serves to announce the earnings results rather than providing detailed financial statements or analysis. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the correct classification is ER with high confidence.
2020-05-15 English
10-Q
Interim / Quarterly Report Q1 2020
2020-05-15 English
8-K ANNUAL MEETING RESULTS
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filing dated May 12, 2020, reporting the results of the company's Annual Meeting of stockholders. It details the voting outcomes on various proposals including director elections, ratification of auditors, reverse stock split approval, and advisory votes on executive compensation. The content is focused on the official results of shareholder votes at the Annual General Meeting. The document length is 4705 characters, which is sufficient to contain detailed voting results rather than just an announcement or a brief summary. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-05-13 English
8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses a notice from Nasdaq regarding the company's non-compliance with the minimum bid price requirement and the extension of the compliance period. This is a regulatory announcement about the company's listing status and compliance with exchange rules, not a financial report, earnings release, or management discussion. The key phrase 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' indicates this is a delisting-related announcement. Therefore, the document fits the category of a Delisting Announcement (DLST). The document length is 4767 characters, which is consistent with a detailed regulatory announcement rather than a brief notice or a full report. Confidence is high given the clear regulatory context and specific Nasdaq listing rule references.
2020-04-23 English
Regulatory Filings 2020
Regulatory Filings
2020-04-06 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.